CST, 99423T, SARS-CoV-2 Spike Protein (S1) (E5S3V) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying Spike Protein SARS-CoV-2. Validated for Western Blotting,Immunohistochemistry (Paraffin),Immunofluorescence (Immunocytochemistry). Available in 2 sizes. Highly specific and rigorously validated in-house, SARS-CoV-2 Spike Protein (S1) (E5S3V) Rabbit Monoclonal Antibody (CST #99423) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunohistochemistry (Paraffin): 1:200 - 1:800 Immunofluorescence (Immunocytochemistry): 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. For a carrier free (BSA and azide free) version of this product see product # 65419 . Protocol Available protocols: Western Blotting, Immunohistochemistry (Paraffin), Immunofluorescence (Immunocytochemistry) Specificity / Sensitivity SARS-CoV-2 Spike Protein (S1) (E5S3V) Rabbit Monoclonal Antibody recognizes endogenous levels of total SARS-CoV-2 spike protein. This antibody detects full-length SARS-CoV-2 spike protein and also detects the S1 domain generated by furin cleavage. This antibody has been confirmed to detect the following SARS-CoV-2 isolates and variants: USA-WA1/2020, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529). This antibody does not cross-react with spike proteins from SARS or MERS coronaviruses. Non-specific nuclear foci staining was observed in some mouse tissues by immunohistochemistry. Species Reactivity: Virus Source / Purification Monoclonal antibody is produced by immunizing animals with recombinant protein corresponding to the S1 domain of SARS-CoV-2 spike protein (USA-WA1/2020 isolate). Background The cause of the COVID-19 pandemic is a novel and highly pathogenic coronavirus, termed SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2). SARS-CoV-2 is a member of the Coronaviridae family of viruses (1). The genome of SARS-CoV-2 is similar to other coronaviruses, and is comprised of four key structural proteins: S, the spike protein, E, the envelope protein, M, the membrane protein, and N, the nucleocapsid protein (2). Coronavirus spike proteins are class I fusion proteins and harbor an ectodomain, a transmembrane domain, and an intracellular tail (3,4). The highly glycosylated ectodomain projects from the viral envelope surface and facilitates attachment and fusion with the host cell plasma membrane. The ectodomain can be further subdivided into host receptor-binding domain (RBD) (S1) and membrane-fusion (S2) subunits, which are produced upon proteolysis by host proteases at S1/S2 and S2' sites. S1 and S2 subunits remain associated after cleavage and assemble into crown-like homotrimers (2,4). In humans, both SARS-CoV and SARS-CoV-2 spike proteins utilize the angiotensin-converting enzyme 2 (ACE2) protein as a receptor for cellular entry (5-7). Spike protein subunits represent a key antigenic feature of coronavirus virions, and therefore represent an important target of vaccines, novel therapeutic antibodies, and small-molecule inhibitors (8,9). Alternate Names 2019-nCoV surface glycoprotein; Peplomer protein; S glycoprotein; SARS-CoV-2 spike protein; spike glycoprotein; SPIKE_SARS2; surface glycoprotein Specification REACTIVITY: Vir SENSITIVITY: Endogenous MW (kDa): 110, 220 Source/Isotype: Rabbit IgG